1. Home
  2. TNXP vs RAC Comparison

TNXP vs RAC Comparison

Compare TNXP & RAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • RAC
  • Stock Information
  • Founded
  • TNXP 2007
  • RAC 2024
  • Country
  • TNXP United States
  • RAC United States
  • Employees
  • TNXP N/A
  • RAC N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • RAC
  • Sector
  • TNXP Health Care
  • RAC
  • Exchange
  • TNXP Nasdaq
  • RAC Nasdaq
  • Market Cap
  • TNXP 335.6M
  • RAC 302.3M
  • IPO Year
  • TNXP N/A
  • RAC 2025
  • Fundamental
  • Price
  • TNXP $26.54
  • RAC $10.27
  • Analyst Decision
  • TNXP Buy
  • RAC
  • Analyst Count
  • TNXP 1
  • RAC 0
  • Target Price
  • TNXP $70.00
  • RAC N/A
  • AVG Volume (30 Days)
  • TNXP 1.9M
  • RAC 160.0
  • Earning Date
  • TNXP 08-11-2025
  • RAC 01-01-0001
  • Dividend Yield
  • TNXP N/A
  • RAC N/A
  • EPS Growth
  • TNXP N/A
  • RAC N/A
  • EPS
  • TNXP N/A
  • RAC N/A
  • Revenue
  • TNXP $9,831,000.00
  • RAC N/A
  • Revenue This Year
  • TNXP $21.19
  • RAC N/A
  • Revenue Next Year
  • TNXP $722.94
  • RAC N/A
  • P/E Ratio
  • TNXP N/A
  • RAC N/A
  • Revenue Growth
  • TNXP N/A
  • RAC N/A
  • 52 Week Low
  • TNXP $6.76
  • RAC $10.00
  • 52 Week High
  • TNXP $130.00
  • RAC $10.70
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 32.47
  • RAC N/A
  • Support Level
  • TNXP $34.50
  • RAC N/A
  • Resistance Level
  • TNXP $29.70
  • RAC N/A
  • Average True Range (ATR)
  • TNXP 3.35
  • RAC 0.00
  • MACD
  • TNXP -1.55
  • RAC 0.00
  • Stochastic Oscillator
  • TNXP 4.29
  • RAC 0.00

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About RAC Rithm Acquisition Corp. Class A Ordinary Shares

Rithm Acquisition Corp is a blank check company.

Share on Social Networks: